Core Viewpoint - A class action lawsuit has been filed against SLM Corporation and certain officers for alleged violations of federal securities laws during the Class Period from July 25, 2025, to August 14, 2025, seeking damages for investors who purchased SLM securities during this time [1] Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the District of New Jersey, under docket number 25-cv-18834, representing all persons and entities, excluding defendants, who invested in SLM securities during the specified Class Period [1] - Investors have until February 17, 2026, to request appointment as Lead Plaintiff for the class [1] Group 2: Company Overview - SLM Corporation, commonly known as Sallie Mae, primarily originates and services private education loans (PELs) to students and their families, emphasizing its "high-quality" PELs and loss mitigation programs [1] - The company classifies PELs as in repayment when borrowers are making interest-only or fixed payments, or have entered full principal and interest repayment status after any applicable grace period [1] Group 3: Financial Metrics and Concerns - Delinquency rates on SLM's PELs are a critical metric for investors assessing the health and profitability of the business [1] - Defendants allegedly misled investors by attributing rising delinquency rates to "normal seasonal trends" and minor refinements in loan offerings, while failing to disclose significant increases in early-stage delinquencies [1] Group 4: Impact of Findings - On August 14, 2025, TD Cowen reported a 49 basis point month-over-month increase in July 2025 delinquencies, contradicting prior reassurances from SLM's executives [1] - Following the TD Cowen report, SLM's stock price fell by $2.67 per share, or 8.09%, closing at $30.32 per share on August 15, 2025 [1]

Core Viewpoint - Pharming Group N.V. is under investigation for potential securities fraud following the FDA's Complete Response Letter regarding its drug Joenja® [1][2] Group 1: Company Overview - Pharming Group N.V. is a biopharmaceutical company focused on developing innovative therapies for rare diseases [2] - The company’s stock, represented by American Depositary Receipts (ADRs), experienced a significant decline of 17.07% following negative FDA news [2] Group 2: FDA Response - On February 1, 2026, the FDA issued a Complete Response Letter for Pharming's supplemental New Drug Application for Joenja® [2] - The FDA raised concerns about potential underexposure in lower weight pediatric patients and requested additional pharmacokinetic data [2] - An issue was also identified with one of the analytical methods used for production batch testing, necessitating further data and clarification [2] Group 3: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Pharming investors regarding possible securities fraud or unlawful business practices by the company and its officers [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [3]

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Ultragenyx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class acti ...

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of T1 Energy Inc. (“T1” or the “Company”) (NYSE: TE).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether T1 and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On January 21, 2026, Culper Res ...

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Mereo and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] During pre- ...

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Telesat Corporation (“Telesat” or the “Company”) (NASDAQ: TSAT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Telesat and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On January 2 ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving BlackRock TCP Capital Corp and its officers or directors [1] Group 1: Company Performance - On January 23, 2026, BlackRock TCP reported a 19% decline in the net asset value of its private corporate loans, attributed to a significant increase in nonperforming loans [3] - Following this announcement, BlackRock TCP's stock price decreased by $0.76 per share, representing a 12.97% drop, closing at $5.10 per share on January 26, 2026 [3] Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of BlackRock TCP to discuss claims related to the company's potential involvement in securities fraud [1] - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Corcept Therapeutics and its officers or directors, following a significant stock price drop after the FDA's Complete Response Letter regarding a new drug application [1][3]. Group 1: Company Overview - Corcept Therapeutics Incorporated is a biopharmaceutical company focused on developing treatments for patients with conditions related to cortisol excess [3]. - The company’s stock price experienced a dramatic decline of $35.40 per share, or 50.42%, closing at $34.80 per share on December 31, 2025, after the FDA issued a Complete Response Letter regarding its drug relacorilant [3]. Group 2: Regulatory Developments - On December 31, 2025, the FDA issued a Complete Response Letter concerning Corcept's New Drug Application for relacorilant, indicating that while the pivotal GRACE trial met its primary endpoint, additional evidence of effectiveness was required for a favorable benefit-risk assessment [3]. Group 3: Legal Investigation - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is currently investigating claims on behalf of investors of Corcept, suggesting potential legal ramifications for the company and its leadership [1][4].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving Carvana Co. and its officers or directors [1] Group 1: Investigation and Allegations - Pomerantz LLP is representing investors of Carvana Co. in an investigation regarding possible securities fraud [1] - Gotham City Research LLC released a short report claiming that Carvana's earnings for 2023-2024 are overstated by over $1 billion and that the company is more reliant on related parties than previously disclosed [3] Group 2: Market Reaction - Following the allegations from Gotham City Research, Carvana's stock price dropped by $67.68 per share, a decline of 14.17%, closing at $410.04 per share on January 28, 2026 [3]

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Vizsla Silver Corp regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Incident and Market Reaction - On January 29, 2026, Vizsla Silver reported a security incident at its project site in Concordia, Mexico, where ten individuals were taken [3]. - Following the incident, Vizsla Silver temporarily suspended certain activities at and near the site [3]. - The stock price of Vizsla Silver fell by $1.02 per share, or 14.87%, closing at $5.84 per share on the same day [3]. Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for the rights of victims of securities fraud and corporate misconduct [4]. - The firm has a track record of recovering multimillion-dollar damages awards for class members [4].